NEW YORK – Opko Health subsidiary BioReference Laboratories announced Monday it has accepted an Indefinite Delivery Indefinite Quantity (IDIQ) contract from the US Centers for Disease Control and Prevention to offer antibody testing for a national serological survey for SARS-CoV-2.
Under the agreement, BioReference will conduct commercial surge capacity testing to determine the seroprevalence of COVID-19 across the US. The firm will also collaborate with the CDC to provide the results with key demographic information and analysis. The contract provides for an indefinite quantity of services from July 20 to Nov. 19, 2020.
"Many studies suggest that the majority of the public has not been infected with COVID-19, but multiple factors limit these findings," said BioReference Executive Chairman Jon Cohen. "Together with the leading public health authority, we are leveraging extensive depth and breadth of testing expertise to increase overall understanding of the disease burden of the virus."
Cohen also announced Monday that BioReference reached an agreement in principle with the National Football League to provide COVID-19 testing. Earlier this month, BioReference announced it will provide PCR diagnostics, rapid diagnostics, and antibody testing for the National Basketball Association's players, referees, and staff.